A Retrospective trial of 90Y-Ibritumomab Tiuxetan after Autologous Stem Cell Transplantation in Intermediate/High-Risk Diffuse Large B-Cell Lymphoma Patients not Responding Adequately
Latest Information Update: 26 Dec 2015
At a glance
- Drugs Ibritumomab tiuxetan (Primary)
- Indications Diffuse large B cell lymphoma
- Focus Therapeutic Use
- 26 Dec 2015 New trial record